Trending...
- Cresteo Scales U.S. Footprint, Partnering with Enterprises to Unlock ROI Through AI-First Solutions
- Naperville, Park District Seek Input on the Riverwalk Grand Pavilion
- Alliant and PCs for People Collect Over 7,000 Pounds of Electronics for Digital Opportunity
Enabling reimbursement and expanded patient access—Effective January 2026
IRVINE, Calif. - illiNews -- VESICA HEALTH®, INC., a precision diagnostics company improving the early detection and management of bladder cancer, today announced that the American Medical Association (AMA) has granted a Proprietary Laboratory Analysis (PLA) billing code for its AssureMDx™ test. The new code, effective January 2026, represents a critical de-risking milestone in Vesica Health's path to commercialization, establishing a recognized billing pathway that will enable reimbursement and support adoption of AssureMDx across the U.S. healthcare system. This achievement positions Vesica Health to accelerate revenue generation and deliver meaningful near-term value creation for our shareholders, while at the same time expanding access for patients.
"Securing a PLA code from the American Medical Association is a foundational milestone," said Christopher Thibodeau, Chief Executive Officer, Vesica Health. "It underscores the continued execution of our commercial strategy to expand access to AssureMDx, drive adoption across the healthcare system, and advance our mission to improve early detection and outcomes for patients, providers, and payers."
The AssureMDx PLA code (0613U) has been published in the AMA's Directory: https://www.ama-assn.org/practice-management/cpt/cpt-pla-codes
By establishing a clear reimbursement pathway, this milestone validates Vesica Health's position with payers, enables provider adoption, expands patient access, and demonstrates the company's ongoing commitment to all stakeholders.
More on illi News
About AssureMDx™
AssureMDx is a proprietary, noninvasive urine-based DNA test clinically validated to improve the early detection of bladder cancer. The assay integrates six genomic and epigenetic biomarkers—DNA methylation of TWIST1, OTX1, and ONECUT2, and somatic mutations in FGFR3, HRAS, and TERT—to stratify hematuria patients for expedited urologic evaluation while safely ruling out those at very low risk.
Vesica Health's genes and technology have been reported in more than 26 peer-reviewed publications involving over 8,500 patients across detection, prognostic, and predictive applications. This body of evidence includes three prospective clinical validation studies evaluating the final six-gene configuration of the AssureMDx assay for early detection. In the largest multicenter study (n=838; van Kessel et al., Journal of Urology, 2020), AssureMDx demonstrated an overall sensitivity of 96%, a negative predictive value greater than 99%, and an AUC of 0.96 for bladder cancer detection. Answering the clinical community's call for earlier, more accurate detection, AssureMDx achieved a combined sensitivity of 95.9% for Stage 0 (Ta and Tis/CIS) and Stage I disease—underpinning its unique ability to identify patients at increased risk for bladder cancer at its earliest and most treatable stages.
AssureMDx has been recognized in the AUA Clinical Guidelines as a validated urine-based genomic test for the evaluation of patients with intermediate-risk microscopic hematuria, further reinforcing its clinical utility within the standard of care.
More on illi News
About Vesica Health®, Inc.
Vesica Health is a privately held precision diagnostics company pioneering noninvasive solutions for the early detection and management of bladder cancer. Hematuria—blood in the urine—affects more than 17 million U.S. adults annually, yet only 12% are referred for urologic evaluation, resulting in an estimated 20,000 missed bladder cancer diagnoses each year.
Headquartered in Irvine, California, Vesica operates a CAP-accredited, CLIA-certified laboratory and holds worldwide commercialization rights for AssureMDx. The company is led by an experienced team with a proven track record in diagnostic development, clinical evidence generation, and commercial execution. In addition to its flagship assay, Vesica is advancing a pipeline that includes recurrence monitoring, prognostic, and predictive companion diagnostics.
Vesica Health is positioned to lead in the $6 billion bladder cancer diagnostics market, with a mission to improve survival and patient care through earlier detection, precision diagnostics, and expanded access to noninvasive solutions. Learn more at: www.vesicahealth.com.
For investment and partnership inquiries, or to learn more about AssureMDx, please contact Vesica Health Corporate Communications at: public.relations@vesicahealth.com
NOTE: The Vesica Health wordmarks and logos, including Vesica Health, and AssureMDx are trademarks or registered trademarks of Vesica Health, Inc. All other trademarks and service marks are the property of their respective owners.
"Securing a PLA code from the American Medical Association is a foundational milestone," said Christopher Thibodeau, Chief Executive Officer, Vesica Health. "It underscores the continued execution of our commercial strategy to expand access to AssureMDx, drive adoption across the healthcare system, and advance our mission to improve early detection and outcomes for patients, providers, and payers."
The AssureMDx PLA code (0613U) has been published in the AMA's Directory: https://www.ama-assn.org/practice-management/cpt/cpt-pla-codes
By establishing a clear reimbursement pathway, this milestone validates Vesica Health's position with payers, enables provider adoption, expands patient access, and demonstrates the company's ongoing commitment to all stakeholders.
More on illi News
- Indies United is pleased to present our October 2025 book releases
- Newest Mako Smartrobotics™ System Used for First Time in the State Of Illinois for Total Joint Replacement Surgery
- $20 Million Annualized Revenue Projected from 20+ Acquisitions and Scaling of Top Quality Dental Labs Across Florida: Standard Dental Labs $TUTH
- Grok Wrote a Direct Message to Elon Musk Discussing Netverse & Phinge CEOs Challenge to Live Debate & Added "it'd be epic to see you two hash it out"
- Foreclosure and Children: The Hidden Impact on the Next Generation
About AssureMDx™
AssureMDx is a proprietary, noninvasive urine-based DNA test clinically validated to improve the early detection of bladder cancer. The assay integrates six genomic and epigenetic biomarkers—DNA methylation of TWIST1, OTX1, and ONECUT2, and somatic mutations in FGFR3, HRAS, and TERT—to stratify hematuria patients for expedited urologic evaluation while safely ruling out those at very low risk.
Vesica Health's genes and technology have been reported in more than 26 peer-reviewed publications involving over 8,500 patients across detection, prognostic, and predictive applications. This body of evidence includes three prospective clinical validation studies evaluating the final six-gene configuration of the AssureMDx assay for early detection. In the largest multicenter study (n=838; van Kessel et al., Journal of Urology, 2020), AssureMDx demonstrated an overall sensitivity of 96%, a negative predictive value greater than 99%, and an AUC of 0.96 for bladder cancer detection. Answering the clinical community's call for earlier, more accurate detection, AssureMDx achieved a combined sensitivity of 95.9% for Stage 0 (Ta and Tis/CIS) and Stage I disease—underpinning its unique ability to identify patients at increased risk for bladder cancer at its earliest and most treatable stages.
AssureMDx has been recognized in the AUA Clinical Guidelines as a validated urine-based genomic test for the evaluation of patients with intermediate-risk microscopic hematuria, further reinforcing its clinical utility within the standard of care.
More on illi News
- Assent Recognized as a Leader in First-Ever Product Compliance Green Quadrant
- Tina Glasneck Launches New Romantasy, A Dragon's Queen, Blending Dragons, Fae Courts, and Forbidden Love
- Announcing the "Utsunomiya Gyoza Festival 2025" to be held November 1 and 2 in Utsunomiya City, Tochigi Pref, Japan
- Lineus Medical Obtains CE Mark for Flagship Product SafeBreak Vascular
- Mayor Brandon Johnson, City Colleges And Greater Chicago Food Depository Collaborate To Launch "Food Security For Life," An Initiative That Aims To End Hunger Among City Colleges Students
About Vesica Health®, Inc.
Vesica Health is a privately held precision diagnostics company pioneering noninvasive solutions for the early detection and management of bladder cancer. Hematuria—blood in the urine—affects more than 17 million U.S. adults annually, yet only 12% are referred for urologic evaluation, resulting in an estimated 20,000 missed bladder cancer diagnoses each year.
Headquartered in Irvine, California, Vesica operates a CAP-accredited, CLIA-certified laboratory and holds worldwide commercialization rights for AssureMDx. The company is led by an experienced team with a proven track record in diagnostic development, clinical evidence generation, and commercial execution. In addition to its flagship assay, Vesica is advancing a pipeline that includes recurrence monitoring, prognostic, and predictive companion diagnostics.
Vesica Health is positioned to lead in the $6 billion bladder cancer diagnostics market, with a mission to improve survival and patient care through earlier detection, precision diagnostics, and expanded access to noninvasive solutions. Learn more at: www.vesicahealth.com.
For investment and partnership inquiries, or to learn more about AssureMDx, please contact Vesica Health Corporate Communications at: public.relations@vesicahealth.com
NOTE: The Vesica Health wordmarks and logos, including Vesica Health, and AssureMDx are trademarks or registered trademarks of Vesica Health, Inc. All other trademarks and service marks are the property of their respective owners.
Source: Vesica Health, Inc.
0 Comments
Latest on illi News
- Red Wing Named Official Work Boot of the Land Improvement Contractors of America
- $750 Million Market Projected to Reach $3.35 Billion; Huge Opportunity for Superior Preservative-Free Ketamine Drug Treating Suicidal Depression $NRXP
- €6.4 Million in Contracts Across Multiple Countries; Smart City Developer; U.S. Expansion, and Announces Strategic Drone Tech Partnership; $AFFU
- CRYPTOCURRENCY: Lucrumia Exchange Platform Addresses Italian Traders' Growing Demand for Secure Digital Asset Trading
- NIUFO Launches Secure Trading Platform for Italian Market Seeking Stability After 20% User Decline
- OrderDomains.com Empowers Businesses with Premium Domains and Flexible Financing
- Cryptocurrency Trading: AHRFD Enters German Market with Institutional-Grade Infrastructure
- TSWHZC Launches Automated Copy Trading Platform for Brazil's 28 Million Crypto Users
- Keyanb Crypto Exchange Unveils Comprehensive Platform Architecture for Chilean Traders Seeking Lower Fees and Enhanced Security
- Industry Leading Jeron Provider® Nurse Call & Workflow Solutions Exhibits at the ANCC National Magnet Conference in Atlanta, October 8-10
- eVertiSKY Deploys "Safety Island":
- Back-to-School, Back-to-Career | Adults Re-Skill with Agile Product Courses
- Phoenix Advocacy Network Launches to Amplify Survivor Voices and Advance Disability Rights
- Matecrypt Platform Delivers Comprehensive Solution for Argentine Traders with 200+ Cryptocurrencies and 2 Million Orders Per Second Processing
- Wzzph Exchange Expands Brazilian Market Access with Comprehensive Trading Platform
- CCHR: Prescription Psychotropics Fuel America's Addiction and Overdose Crisis
- The Truth Behind Egypt's Stolen Legacy: Livestream
- Digital Pharma Advances 2026: AI and Patient-Centric Strategies Transform Pharma Marketing
- 'ChilCorp – Water' Builds Momentum After Being Named as a Qualified Team in $119M XPRIZE Water Scarcity Global Competition
- Cryptocurrency Exchange AZETHIO Targets US Market Security Concerns with MPC Technology and 15-Minute KYC Verification